Antares Pharma reports Q3 EPS (1c) vs. (3c) last year
Reports Q3 revenue $17.87M, consensus $15.05M. "The third quarter of 2018 was exceptional for the Company with record revenue reported and a significant number of operational achievements highlighted by the approvals of XYOSTED and Teva's generic EpiPen. Antares also entered into an agreement with Pfizer to develop a rescue pen utilizing our QuickShot device with an undisclosed drug. This is an exciting opportunity and enhances our expanding pipeline of proprietary and partnered products. We believe each one of these important milestones will help drive positive momentum during the balance of this year and beyond. We look forward to the 2018 launch of XYOSTED, the only subcutaneous auto injector product approved for testosterone deficiency as well as Teva's launch of the first and only fully substitutable generic EpiPen. We believe these new sources of revenue, combined with the revenue stream from the Makena auto injector, which was also FDA approved and launched in 2018, will ultimately increase shareholder value," said CEO Robert Apple earlier this morning as part of the company's Q3 earnings report press release.